119 related articles for article (PubMed ID: 1477650)
1. Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Holowiecki J; Koehler M; Zintl Z; Kardos G; Lutz D; Krzemien S; Rewesz T; Brugiatelli M; Callea V; Kachel L
Leuk Lymphoma; 1992 Jun; 7(3):225-34. PubMed ID: 1477650
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.
Hann IM; Richards SM; Eden OB; Hill FG
Leukemia; 1998 Aug; 12(8):1249-55. PubMed ID: 9697880
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
5. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
[TBL] [Abstract][Full Text] [Related]
6. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of the reaction to steroids in the treatment of acute lymphoblastic leukemia in children].
Urasiński T; Peregud-Pogorzelski J; Bartoszewicz L
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):360-2. PubMed ID: 1437754
[TBL] [Abstract][Full Text] [Related]
8. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86.
Ludwig WD; Harbott J; Bartram CR; Komischke B; Sperling C; Teichmann JV; Seibt-Jung H; Notter M; Odenwald E; Nehmer A
Recent Results Cancer Res; 1993; 131():269-82. PubMed ID: 8210646
[No Abstract] [Full Text] [Related]
9. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
[No Abstract] [Full Text] [Related]
10. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
11. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
12. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
[TBL] [Abstract][Full Text] [Related]
13. [Incidence, clinical markers and prognostic significance of immunologic subtypes of acute lymphoblastic leukemia (ALL) in children: experiences of the ALL-BFM 83 and 86 studies].
Ludwig WD; Teichmann JV; Sperling C; Komischke B; Ritter J; Reiter A; Odenwald E; Sauter S; Riehm H
Klin Padiatr; 1990; 202(4):243-52. PubMed ID: 2203938
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia.
Nakamura A; Tsurusawa M; Kato A; Taga T; Hatae Y; Miyake M; Mimaya J; Onodera N; Watanabe A; Watanabe T; Kanegane H; Matsushita T; Iwai A; Hyakuna N; Gushi K; Kawakami T; Sekine I; Izichi O; Asami K; Kikuta A; Tanaka A; Fujimoto T;
Leuk Lymphoma; 2001 Jul; 42(3):393-8. PubMed ID: 11699404
[TBL] [Abstract][Full Text] [Related]
15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
16. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
[TBL] [Abstract][Full Text] [Related]
17. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Kudva GC; Chandy M; Dennison D; Srivastava A; Bhushan V
Indian J Cancer; 1994 Mar; 31(1):1-7. PubMed ID: 8063329
[TBL] [Abstract][Full Text] [Related]
19. [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
Vivanco Martínez JL; López Pérez J; Melero Moreno C; Torres Valdivieso MJ; Palacios López ME; Contra Gómez T; Martín Ramos N; Bernacer Borja M; Gil López C; Valverde Moreno F
An Esp Pediatr; 1998 Dec; 49(6):603-8. PubMed ID: 9972623
[TBL] [Abstract][Full Text] [Related]
20. Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis.
Aziz Z; Zahid M; Mahmood R; Maqbool S
Med Pediatr Oncol; 1997 Jan; 28(1):48-53. PubMed ID: 8950336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
